ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO108

Interferon-Inducible Protein 10 and Disease Activity in Patients with Systemic Lupus Erythematous and Lupus Nephritis: A Systematic Review and Meta-Analysis

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders


  • Puapatanakul, Pongpratch, Chulalongkorn University, Bangkok, Thailand
  • Chansritrakul, Sonchai, Chonburi Hospital, Chonburi, Thailand
  • Susantitaphong, Paweena, Chulalongkorn University, Bangkok, Thailand
  • Eiam-Ong, Somchai, Chulalongkorn University, Bangkok, Thailand
  • Praditpornsilpa, Kearkiat, Chulalongkorn University, Bangkok, Thailand

There has been increasing evidence regarding correlation between serum as well as urine interferon-inducible protein 10 (IP-10) and disease activity of systemic lupus erythematous (SLE) patients.


We conducted a comprehensive search on PubMed, Scopus, and Cochrane electronic database through the end of December 2016. All studies that measured serum or urine IP-10 using enzyme immunoassay (EIA) in SLE patients with or without lupus nephritis (LN) were retrieved. Meta-analysis of correlation between each test and disease activity was performed using a random-effects model.


Thirteen studies measured either serum or urine IP-10 levels in SLE/LN patients. However, only 9 and 4 studies provided adequate data of serum and urine IP-10 levels, respectively in 396 active SLE,175 active LN, 442 inactive SLE patients, and 310 non-SLE controls. Serum IP-10 levels were significantly higher in active SLE than in non-active SLE patients (mean difference [MD] 365.8 pg/mL, 95% CI 262.8 to 468.7, p < 0.001) but were indifferent between patients with active and non-active LN (MD 18.8 pg/mL, 95% CI -136.7 to 174.3, p = 0.813). Serum IP-10 also showed positive correlation with disease activity in SLE and LN patients (pooled r = 0.28, 95% CI 0.20 to 0.37, p < 0.001; pooled r = 0.26, 95% CI 0.08 to 0.43, p = 0.006; respectively). Urine IP-10 levels were comparable between active and non-active SLE patients (MD 2.44 pg/mgCr, 95% CI -0.50 to 5.38, p = 0.10) but were significantly higher in active LN patients compared to non-active LN patients (MD 4.57 pg/mgCr, 95% CI 1.68 to 7.47, p = 0.002). Urine IP-10 also had positive correlation with disease activity in SLE and LN patients (pooled r = 0.21, 95% CI 0.05 to 0.36, p = 0.011; pooled r = 0.40, 95% CI 0.13 to 0.62, p = 0.005; respectively).


Serum and urine IP-10 levels demonstrate positive correlation with disease activity in both SLE and LN patients. However, an increase in serum IP-10 is more pronounced in active SLE while urine IP-10 showed a significant increase mainly in active LN.